Prognostic biomarkers for patients with melanoma after lymph node resection are of clinical relevance and could thus enable the identification of patients who therefore would most benefit from adjuvant treatment. The aim of this work was to determine, using an in vitro model, whether immune-related biomarkers, such as MHC-class I and II, melanoma-associated antigens, IDO1 and PD-L1, could also be relevant to predict the risk of relapse of patients with stage III melanoma after lymph node resection. We established tumor cell lines from metastatic lymph nodes of 50 patients with melanoma. The expression of investigated biomarkers was determined on untreated and IFN-γ treated melanoma cell lines using flow cytometry. Among the selected biomarkers, the IFN-γ-induced expression of PD-L1 and IDO1 was associated with an increased risk of relapse (P = .0001 and P = .013, respectively) and was also associated with death for IDO1 (P = .0005). In the future, this immunologic signature could permit the identification of patients at higher risk of relapse and justifying an adjuvant treatment using immunotherapy.
| INTRODUC TI ON
Malignant melanoma is the most aggressive cutaneous malignancy with 132 000 new cases occurring worldwide each year (World Health Organization, Skin Cancers) and an annual 3%-7% increase in the incidence rate for Caucasians. [1] Despite the therapeutic revolution brought by innovative treatments such as targeted therapies (BRAF inhibitors), or immune checkpoint inhibitors (ie PD-1/PD-L1 or CTLA-4/B7 antibodies), the identification of biomarkers capable of predicting patient prognosis after lymph node resection is still of clinical relevance. Furthermore, new treatments are arriving in the adjuvant setting for stage III melanoma, increasing the interest to select patients with higher risk of relapse. [2] Consequently, attention has been focused on finding biomarkers to identify patients most likely to respond to a specific cancer therapy. Thus, tumor gene expression profiling is a powerful technique for identifying prognostic gene signatures (GSs). [3, 4] Predictive
GSs have also been reported in colorectal [5] and gastric cancers. [6] Moreover, both prognostic and predictive GSs have been identified in non-small-cell lung cancer (NSCLC) and breast cancer. [7, 8] Recently, a 84-gene GS associated with clinical response to MAGE-protein immunizations has been identified in metastatic Abbreviations: AJCC, American Joint Committee on Cancer; CTA, cancer testis antigens; DNA, desoxyribonucleic acid; GS, gene signature; H&E, haematoxylin & eosin; HMW-MAA, high molecular weight-melanoma-associated antigen; IDO1, indoleamine 2,3 dioxygenase; LN, lymph node; MAA, melanoma-associated antigens; mAb, monoclonal antibody; MAGE-A, melanoma-associated antigen-A; MCSP, melanoma chondroitin sulphate proteoglycan; MHC, major histocompatibility complex; NSCLC, non-small-cell lung cancer; NY-ESO-1, New York oesophageal squamous cell cancer-1; OS, overall survival; PCR, polymerase chain reaction; PD-L1, programmed death ligand 1; P, progression; RC, complete response; RECIST, response evaluation criteria in solid tumor; RFS, relapse-free survival; RP, partial response; SSM, superficial spreading melanoma; St, stabilization; TRP2, tyrosinase-related protein 2. melanoma. [9] These results were confirmed in resected NSCLC. [10] It was the evidence that clinical response resulting from a cancer immunotherapeutic treatment may be associated with an immune biomarker signature in two different settings (metastatic and adjuvant) and in two tumor types (melanoma and NSCLC). The genes differentially expressed were genes involved in antigen processing, MHC-class I and II, T-cell markers such as CD3 and CD8 and chemokines such as CCL5, CXCL9 and CXCL10.
Meanwhile, a 46-gene GS with strong overrepresentation of immune response genes was identified in 79 patients with stage III melanoma, suggesting that BRAF mutation, NRAS mutation and the absence of an immune-related expressed gene profile predicted poor outcome in patients with stage III melanoma. [11] The genes differentially expressed were CCL5, CXCL9, CXCL10, MHC-class II, MAGE-C2, CD2, CD3 and CD8.
The aim of this work was to assess whether modulation of some biomarkers expressed by melanoma cell lines, obtained from metastatic regional lymph nodes (LN) and exposed to IFN-γ, could be an in vitro prognostic tool useful to identify stage III melanoma patients with a higher risk of relapse and a shorter overall survival. For this purpose, we analysed expression of some immune-related biomarkers (MHC-class I and II) and melanoma-associated antigens. We also tested expression of PD-L1 and IDO1, two biomarkers known to be modulated by IFN-γ and recently identified as enabling melanoma cells to escape immune destruction despite antitumor responses. [12] [13] [14] [15] 2 | MATERIAL S AND ME THODS
| Patients with melanoma
A total of 50 patients with stage IIIb (AJCC 2007) melanoma were included in this study (Table 1) . For each patient, a melanoma cell line was obtained from a fragment of a metastatic lymph node (LN). Written informed consent was provided by all patients, and the study was approved by the Ethics Committee of Pays de La Loire and Health Authorities (France). The 1964 Declaration of Helsinki protocols and its later amendments or comparable ethical standards were applied in this study.
| Establishment of melanoma cell lines
Melanoma cell lines were established for the 50 tumor samples as previously described by us [16, 17] and by others. [18] Briefly, fresh tumor samples were minced into small tumor pieces in wells of 24-well plates (NUNC) with RPMI medium supplemented with 10%
foetal calf serum (FCS). Plates were placed at 37°C in a humidified incubator with 5% CO 2 and observed under a light microscope every week and subcultured when necessary.
| Experiments on melanoma cell lines
For each cell line, a total of 500 000 cells per well of a 6-well plate were seeded in 3 mL of culture medium with or without 500 U/mL recombinant IFN-γ (Tebu, Le Perray en Yvelines, France), in duplicate.
After 48 hours of incubation, cells were washed, detached from the wells using PBS-EDTA (Lonza, Levallois, France) and processed for flow cytometry. and #555557, dilution 1/100, Le Pont de Claix, France) as previously described. [19] For intracellular staining, 0.2 × 10 6 cells were rinsed twice in DPBS, permeabilized using fixation/permeabilization buffer set (eBioscience, A difference comprised between −5% and −10% in the expression of a given biomarker after IFN-γ treatment compared with before IFN-γ treatment was considered as a moderate decrease. (AIC). The threshold of significance was set at 5% in bilateral situation. The R 3.11 statistical software was used for all analyses. All quantitative data were scaled.
| Antibodies and flow cytometry
#00
| Statistical analysis

| RE SULTS
A total of 50 patients with stage IIIb (AJCC 2007) melanoma were included in this study. The main clinical features of these patients are summarized in Table 1 , and detailed clinical characteristics of the 50 patients are summarized in Table 2 . Mean age was 51.9 ± 11.6 years (median: 53; min.-max.:27-72), with 35 men and 15 women.
Median event-free survival was 8 months, and median survival was 19.5 months.
| Expression levels of selected biomarkers by untreated and IFN-γ-treated melanoma cell lines
No Table 3 and Table S1 ).
Most untreated melanoma cells expressed MCSP, gp100,
Melan-A and tyrosinase and also MHC-class I and MHC-class II antigens (Table 3 and Table S1 ). Upon IFN-γ treatment, MHC-class II expression was increased, whereas MCSP and MHC-class I expressions
were not modified, and gp100, Melan-A and tyrosinase expressions were moderately decreased (Table 3 and Table S1 ). Half of untreated melanoma cells expressed NY-ESO-1 and MAGE-A antigens, and their expression was decreased upon IFN-γ in vitro stimulation (Table 3 and Table S1 ).
| Significant associations between selected biomarkers and RFS
| Univariate analysis
None of the clinical features was significantly associated with RFS (for Kaplan-Meier curves, see Figure S1 ). No relationship was observed between the 10 selected biomarkers in untreated melanoma cell lines and RFS except for MAGE-A expression (P = .021) and also no relationship between biomarkers in IFN-γ-treated melanoma cell lines and RFS except for tyrosinase (P = .012) (Table S2 and Figure S1 for Kaplan-Meier curves).
| Multivariate analysis
Biomarkers in untreated melanoma cell lines
The expression of MCSP in untreated melanoma cell lines was associated with an improved RFS (P = .026) ( Table S3 ). The other biomarkers were not significantly associated with RFS. 
Biomarkers in IFN-γ-treated melanoma cell lines
The induction of PD-L1 and IDO1 expressions in IFN-γ-treated cell lines was significantly associated with a decreased RFS (respectively, P = .0001 and P = .013) (Table S4 ). Regarding melanoma-associated antigens (MAA), the decreased expression of tyrosinase in IFN-γ-treated cell lines was associated with an improved RFS (P = .0013), whereas the decreased expression of NY-ESO-1 in IFN-γ-treated cell lines was significantly associated with a decreased RFS (P = .0005).
The unmodified expression of MCSP upon IFN-γ stimulation was associated with an improved RFS (P = .01). The other biomarkers were not significantly associated with RFS.
Other clinicobiological markers NRAS mutation status was associated with an improved RFS (P = .0015) ( Table S4 ). The number of invaded LNs was significantly associated with a poor RFS (P = .0175). The other clinical markers
were not significantly associated with RFS.
| Significant associations between selected biomarkers and OS
| Univariate analysis
We observed that none of the clinical features was significantly associated with OS (for Kaplan-Meier curves, see Figure S2 ). No relationship was observed between the 10 selected biomarkers in untreated melanoma cell lines and OS except for MAGE-A and NY-ESO-1 (respectively, P = .0073 and P = .044). In addition, no relationship was identified between these biomarkers in IFN-γ-treated melanoma cell lines and OS (Table S5 and Figure S2 for KaplanMeier curves).
| Multivariate analysis
Biomarkers in untreated melanoma cell lines
The expression of tyrosinase was associated with an improved OS (P = .003) ( Table S6 ). The other biomarkers were not significantly associated with OS. 
TA B L E 2 (Continued)
Biomarkers in IFN-γ-treated melanoma cell lines
The induction of IDO1 expression by IFN-γ was significantly associated with a decreased OS (P = .0005) ( Table S7 ). The decreased expression of gp100 and MAGE-A by IFN-γ was associated with an improved OS (respectively, P = .007 and P = .023), whereas the decreased expression of Melan-A by IFN-γ was significantly associated with a decreased OS (P = .028). The unmodified expression of MCSP upon IFN-γ stimulation was associated with an improved OS (P = .02).
The other biomarkers were not significantly associated with OS.
Other clinicobiological markers
High Breslow index and capsular breaking were significantly associated with a poor OS (respectively, P = .03 and P = .0026) ( Table S7 ).
The other clinical markers were not significantly associated with OS.
| D ISCUSS I ON
In the present work, we conducted a multivariate analysis of clinical and pathological determinants of outcome and several immunerelated biomarkers, melanoma-associated antigens and two important biomarkers of immune relevance in melanoma: IDO1 and PD-L1.
First, we observed that most untreated melanoma cell lines did not express IDO1. Moreover, the induction of IDO1 expression by IFN-γ treatment was significantly associated with both decreased RFS and OS, making IDO1 the only biomarker associated with both RFS and OS in this study. IDO1 is an intracellular enzyme that degrades tryptophan to kynurenine, inducing a local immunosuppression through deficiency in this essential amino acid, which is needed for the activity of T cells. [20] There is evidence that IFN-γ stimulates IDO1 gene transcription in many cell types. [21, 22] In melanoma, IDO1
has been shown to be increased in both primary and metastatic lesions and its expression correlated with increased invasiveness and disease relapse rate. [12, 13] We recently reported an induction of PD-L1 expression by melanoma cells when cocultivated with IDO1 expressing foetal fibroblasts. [23] We assumed that this induction of PD-L1 by IDO1 may contribute to inhibit the efficacy of adoptive cell therapy using TILs, by inducing inactivation of lymphocytes, decreasing both their survival and proliferation. This way, IDO1 appears as a molecule that may play a major role in immune tolerance induction, in melanoma microenvironment.
We also observed that untreated melanoma cells did not express PD-L1. Interestingly, the induced expression of PD-L1 in IFN-γ-treated cell lines was significantly associated with a decreased RFS. It is well known that many malignant cells express PD-L1, either constitutively or after IFN-γ induction. [24, 25] PD-L1 expression has been described as having multiple prognostic significances, depending on the tumor type. It has been correlated with decreased survival in ovarian, pancreatic and renal cell carcinomas [26] [27] [28] and has been associated with an improved survival in patients with Merkel cell, [29] breast [30] and cervical carcinomas. [31] Conflicting reports also exist regarding its significance in melanoma. [14, 15] However, all these studies were conducted on tumor tissue samples and not on in vitro tumor cell lines. ing from moderate induction to suppression. [32] Moreover, upon IFN-γ stimulation, we observed that the decreased expression of tyrosinase was associated with an improved RFS and the decreased expression of gp100 to an improved OS, whereas the decreased expression of Melan-A was associated with a decreased OS. Our conflicting results regarding the predictive value of MAA perfectly illustrates the fact that data on this subject are controversial. [33] [34] [35] Finally, we report that the unmodified MCSP expression in IFN-γ-treated melanoma cell lines was related to both increased RFS and OS. MCSP/HMW-MAA is highly expressed in more than 85% of melanomas [36] and is thought to contribute to the malignant phenotype of melanoma cells via enhancement of their spreading, invasion and migration. [37] To our knowledge, no data exist to date regarding the predictive or prognostic value of MCSP expression level in melanoma.
Regarding cancer testis antigens (CTA), we observed here that the decreased expression of MAGE-A was associated with an improved OS, whereas the decreased expression of NY-ESO-1 was associated with a diminished RFS. This result is consistent with our previous study reporting that the expression of MAGE-A1 and MAGE-A3 but in contradiction for NY-ESO-1 which was significantly associated with a higher RFS in patients with stage III melanoma. [38] However in the present work, we used flow cytometry to determine the expression level of tumor-associated antigens on melanoma cell lines, whereas in our work published in 2009, we used a semiquantitative RT-PCR analysis on melanoma tissue specimens.
In primary cutaneous melanoma, Svobodova et al reported that the median RFS of patients with the three CTA (MAGE-A1, MAGE-A4 and NY-ESO-1)-positive tumors was significantly reduced compared to those of patients with CTA-negative tumors. [39] We finally observed that NRAS mutation status was associated with an improved RFS. However, controversial data exist in the literature on this subject. For instance, Ekedahl et al observed a trend showing a better prognosis for patients with NRAS-mutant tumors compared with BRAF V600E-mutant tumors, [40] although other studies reported an association between NRAS mutation and worse prognosis in stage IV melanoma [41] but also in stage III melanoma. [11] One of the limitations of our work is that it is not always possible to obtain melanoma cell lines and the delay for obtaining it. In our experience, we managed to obtain cell lines for 80% of our patients.
The median time necessary to obtain the cell lines was 2 months after complete lymph node resection. This is not so long as compared to inclusion in a clinical trial. Furthermore, the adjuvant treatment could be initiated before obtaining the cell line and changed when the data become available.
In conclusion, our results suggest that it is possible to identify a dynamic prognostic immunological profile of melanoma cells, for stage III melanoma patients with lymph node involvement.
Melanoma cell lines treated with IFN-γ could be an interesting tool to identify stage III melanoma patients with a higher risk of relapse.
Thus, we propose that the modulation of PD-L1 and IDO1 expressions in melanoma cell lines incubated with IFN-γ could help screening patients most at risk of relapse and shorter overall survival.
These biomarkers have a prognostic value on RFS and OS. In the future, this immunological profile of melanoma cells could help to identify stage III melanoma patients with a higher risk of relapse and thus justifying an adjuvant treatment. Today, this last point is highly relevant because of new treatments costs, but also adverse events occurrence, that can persist despite stopping treatment.
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